[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) Form 144 notice shows a proposed sale of 74,000 common shares through Morgan Stanley Smith Barney on 09/05/2025 for an aggregate market value of $3,932,056.60. The filing reports 191,168,504 shares outstanding and lists the exchange as NASDAQ. The shares to be sold were acquired on 09/05/2025 by stock option exercise from the issuer and paid for in cash.

The filing also discloses a prior sale by Frank P. McCormick of 100,000 common shares on 06/24/2025 producing gross proceeds of $4,422,800.00. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

Positive

• Transaction disclosed with broker details (Morgan Stanley Smith Barney) supporting regulatory transparency
• Securities were acquired by stock option exercise and paid in cash, which clarifies the nature of acquisition

Negative

• Insider sales disclosed: 100,000 shares sold on 06/24/2025 and 74,000 proposed for 09/05/2025, indicating insider liquidity
• No information provided on trading plan or blackout compliance within this filing

Insights

Securities Analyst

TL;DR: Insider sold 74,000 shares via option exercise and previously sold 100,000 shares—routine insider liquidity, no new operational detail.

The Form 144 documents an insider liquidity event rather than operational developments. The current notice covers 74,000 shares acquired and to be sold on 09/05/2025 via Morgan Stanley Smith Barney, with acquisition by stock option exercise and cash payment. A prior sale by Frank P. McCormick of 100,000 shares on 06/24/2025 generated $4.42 million. These disclosures are standard for compliance with Rule 144 and provide transparency about insider selling; they do not include financial performance, guidance, or new corporate actions.

Corporate Governance Expert

TL;DR: The filing is a compliance disclosure of insider sales; it raises governance transparency but contains no governance concerns by itself.

The notice meets Rule 144 requirements by listing broker, number of shares, and acquisition details. The seller represents no undisclosed material adverse information. The combination of a recent large sale and a new sale is noteworthy for monitoring but is a permissible, disclosed liquidity action. No information about any trading plan, hedging, or blackout periods is provided in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	74000	3932056.60	191168504	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Stock Option Exercise	Issuer			74000	09/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
FRANK P. MCCORMICK 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	06/24/2025	100000	4422800.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the BBIO Form 144 disclose about the proposed sale?

The notice discloses a proposed sale of 74,000 common shares on 09/05/2025 via Morgan Stanley Smith Barney with aggregate market value of $3,932,056.60.

How were the 74,000 BBIO shares acquired?

The filing states the shares were acquired on 09/05/2025 by stock option exercise from the issuer and the payment was made in cash.

Did the filer sell other BBIO shares recently?

Yes. The filing reports a prior sale by Frank P. McCormick of 100,000 common shares on 06/24/2025 for gross proceeds of $4,422,800.00.

On which exchange will the BBIO shares be sold?

The proposed sale is listed to occur on NASDAQ through Morgan Stanley Smith Barney.

Does the filing state any undisclosed material information about BridgeBio (BBIO)?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.